Background and Purpose-The potential detrimental effect of diabetes mellitus and admission glucose level (AGL) on outcomes after stroke thrombolysis is unclear. We evaluated outcomes of patients treated by intravenous and/or intraarterial therapy, according to diabetes mellitus and AGL. Methods-We analyzed data from a patient registry (n=704) and conducted a systematic review of previous observational studies. The primary study outcome was the percentage of patients who achieved a favorable outcome (modified Rankin score ≤2 at 3 months). Results-We identified 54 previous reports that evaluated the effect of diabetes mellitus or AGL on outcomes after thrombolysis. In an unadjusted meta-analysis that included our registry data and previous available observational data, diabetes mellitus was associated with less favorable outcome (odds ratio 
U p to 60% of acute ischemic stroke (AIS) patients will experience hyperglycemia, depending on its definition. 1, 2 Poststroke hyperglycemia (PSH) is associated with poor clinical outcome and death [2] [3] [4] and is commonly considered to represent an underlying impaired glucose tolerance or unrecognized diabetes mellitus. More often this process is the result of stress hyperglycemia, 1,2 which is usually defined as a hyperglycemia resolving spontaneously after acute illness dissipation. 5 Several mechanisms have been proposed to explain the observed adverse effects of PSH on clinical outcome, including increased blood-brain barrier disruption with higher hemorrhagic risk 6, 7 ; or increased lactic acid production in ischemic tissue leading to a greater infarct size. 8 In patients with AIS treated with intravenous (IV) thrombolysis (IVT), several large studies reported an association between diabetes mellitus or PSH and unfavorable outcome, hemorrhagic transformation, and death after IVT. 9, 10 Other series showed that PSH or diabetes mellitus were associated with lower recanalization rates in patients with stroke treated with IVT. 11, 12 However, a recent study found that IVT-treated patients with PSH did not have significantly worse outcomes. 13 Data on PSH or diabetes mellitus in endovascular therapy-treated patients are limited. [14] [15] [16] [17] [18] [19] Available studies have shown conflicting results with respect to a potential detrimental effect of diabetes mellitus and PSH on clinical outcome. In opposition to the aforementioned IVT studies, Informed consent was obtained from the patient or their representative, and the research protocol was approved by the Ethics Committee from Ambroise Paré Hospital.
Data Collection and Definitions
Information on patients' demographic characteristics, medical history, current medications, laboratory and imaging findings, vital signs before treatment, National Institutes of Health Stroke Scale (NIHSS) scores (at admission, and at 1, 3, and 24 hours after the initiation of treatment), 23 clinical outcomes were collected prospectively using a structured questionnaire. Times from symptom onset (or from when the patient was last seen in a normal condition) to initiation of treatments were also recorded. All patients had a computed tomography or MRI scan 24 hours after treatment onset to assess hemorrhagic complications. For patients receiving IA therapy, the recanalization status of the occluded artery was monitored with conventional angiography, and the time to recanalization was noted. Recanalization was measured with the Thrombolysis In Myocardial Infarction (TIMI) score 24 by 2 members of staff (E.M. and M.M.), and was used for all imaging modalities. Modified Rankin Scale at 3 months was assessed during face-to-face interviews or via telephone calls by a senior vascular neurologist (E.M. or M.M.), who was certified for modified Rankin Scale scoring. 25 
Outcome Definitions
The primary study outcome was the percentage of patients who achieved a favorable outcome, defined as an modified Rankin Scale score of 0 to 2 at 90 days. Secondary outcomes included excellent outcome (defined as an modified Rankin Scale score of 0-1 at 90 days), early neurological improvement (defined as an NIHSS score of 0-1 at 24 hours or a decrease of ≥4 points in NIHSS score at 24 hours), any recanalization (defined by TIMI 2-3), complete recanalization (defined by TIMI 3), 90-day mortality, hemorrhagic complications, and symptomatic intracerebral hemorrhage (defined as a hemorrhage on the follow-up computed tomography/MRI scan associated with an increase of ≥4 points in NIHSS score).
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Systematic Review Search Strategy and Study Selection
We performed a computerized PubMed search of articles published between January 1996 and May 2012 to identify all observational and interventional studies that investigated the effect of history of diabetes mellitus or AGL on efficacy or safety outcomes in patients with AIS treated by an IV or IA strategy. We used the search terms (thrombolysis OR fibrinolysis OR thrombolytic OR intravenous OR intra-arterial OR intra-arterial OR endovascular OR mechanical OR thrombectomy OR clot removal OR clot disruption) AND stroke, without any language restriction. One author (J.L.) selected potentially relevant articles based on the title and abstract, and obtained the full text for detailed review. We also searched the reference lists of retrieved articles and published review articles for additional studies. Studies were selected using the following criteria: (1) if they involved subjects aged ≥18 years; (2) were retrospective or prospective (observational or interventional) studies with ≥100 patients with AIS treated by IV or IA approach; and (3) reported a statistical analysis on the association of outcomes (efficacy or safety) with history of diabetes mellitus or AGL. We did not select studies according to treatment strategy, time to treatment, or the reported outcome definitions. We screened duplicate publications based on the same data sets (ie, where data overlapped with data in other included studies). When multiple end points were reported in separate publications, or when impacts of diabetes mellitus history and AGL were reported in separate publications, duplicate publications were included. For other duplicate publications, only the report with the most complete data was included.
Data Extraction
Two authors (J.L. and J.P.D.) independently extracted data using a standardized form, and any disagreement was resolved by consensus. We did not contact the authors of the studies to request incomplete or unpublished data. We collected the following data: report characteristics (first author's name, journal, year of publication); study design (country, study period, number of centers, AIS treatment [IV agents, IA chemical agents, IA mechanical therapy]); study sample (sample size, age, sex, admission NIHSS, time from symptom onset to treatment), incidence and definition of outcomes (functional outcome, neurological improvement, recanalization, mortality, intracranial hemorrhage), direction of association between diabetes mellitus (or AGL) and each outcome, and, if available, a measure of the strength of the association in univariate and multivariate analysis.
Statistical Analysis
Statistical testing was done at the 2-tailed α level of 0.05, except in tests for homogeneity in which an α level of 0.10 was used. Data were analyzed using the SAS software version 9.3 (SAS Institute, Cary, NC).
Bichat Clinical Registry
We made univariate comparisons between patients with and without history of diabetes mellitus, using χ 2 tests for categorical variables and Student t test for continuous variables (Mann-Whitney U test was used for non-Gaussian distributions). Associations between baseline characteristics and AGL were performed using linear regression analysis. We investigated the effects of diabetes mellitus history and AGL on clinical and recanalization outcomes using a logistic regression model adjusted for potential confounding factors selected on the basis of their significance with diabetes mellitus or glucose in univariate analyses (P<0.20). To check the linearity of the by guest on April 28, 2017 http://stroke.ahajournals.org/ Downloaded from associations of AGL and outcomes, we categorized the AGLs into quartiles and calculated odds ratios (ORs; and their 95% confidence intervals [CIs] ) for the upper 3 quartiles relative to the lowest quartiles. Because ORs increased gradually with AGL quartiles, we also computed OR per 1 SD increase in AGL. Finally, among patients who achieved recanalization after IA therapy, we investigated the association of time to recanalization with diabetes mellitus history and AGL using Mann-Whitney U test or Spearman rank correlation analysis, respectively. Adjustment for confounding factors was done using nonparametric covariance analysis. 
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We reported AGLs using the conventional unit (mg/dL). When necessary, we converted the standard unit (mmol/L) to the conventional unit by dividing by 0.0555. Using all available data, we calculated for each study, the unadjusted effect size for diabetes mellitus as ORs (and their 95% CIs) of functional outcome and symptomatic intracranial hemorrhage (sICH), using patients without history of diabetes mellitus as reference group. Because a majority of retrieved studies reported means (±SD) of AGL according to presence or absence of outcome, we calculated the unadjusted effect size as the standardized mean difference between patients with and without good outcome, or between patients with and without sICH. When means (±SD) were not available, we approximate the effect size using medians (interquartile range) or converting the OR associated with glucose cut-off level. 27 We combined the available unadjusted effect sizes using the inverse-variance weighted random-effects model; heterogeneity between studies was examined using the χ 2 test for homogeneity followed by the calculation of the I 2 statistic. We performed a sensitivity analysis by excluding data from the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register (SITS-ISTR), 9 because they contributed to >70% of combined data and because we cannot exclude the possibility that several studies in our meta-analysis may have participated in SITS-ISTR. Sensitivity analyses restricted to the studies analyzed our primary study outcome (ie, favorable outcome), or those restricted to the studies where the effect size was not approximated were also reported. Finally, we extracted and combined the available multivariate results; for AGL, we calculated the adjusted OR per 18 mg/dL (=1 mmol/L) increase in glucose values.
Results
Bichat Clinical Registry
Seven hundred thirty-three consecutive patients with AIS were treated with IV or IA therapy. Of these, 29 were excluded because no information on history of diabetes mellitus could be obtained (n=4), or missing AGL (n=18) or patients were lost to follow-up after discharge (n=7; Figure I in the onlineonly Data Supplement); finally, 709 patients were analyzed. In the study sample, 104 patients (15%) had history of diabetes mellitus, and the mean (SD) AGL was 133 (45) mg/dL. Baseline characteristics of patients with and without history of diabetes mellitus are described in Table 1 . Patients with diabetes mellitus were older, more often men, and more often 
Diabetes Mellitus and Outcomes
In univariate analysis as well as multivariate analysis, we found no significant differences for all study clinical outcomes regarding diabetes mellitus history (Table 2 ). In addition, among the 240 patients who received IA therapy, there was no significant difference in recanalization rates between the diabetes mellitus subgroups. Rate of any recanalization (TIMI 2-3) was 66.7% in patients with history of diabetes mellitus and 74.3% in the group without (P=0.38); complete recanalization rates were, respectively, 40.0% and 49.5% (P=0.33). In multivariate analysis, the OR associated with diabetes mellitus was 0.89 (95% CI, 0.37-2.12; P=0.79) for any recanalization and 0.97 (95% CI, 0.42-2.22; P=0.94) for complete recanalization. In the subset of patients who achieved any recanalization (n=176), the median time from symptom onset to recanalization was 285 minutes (interquartile range, 255-311 minutes) in patients with history of diabetes mellitus and 245 minutes (interquartile range, 212-333 minutes) in the group without (unadjusted/adjusted P=0.080/0.052).
Admission Blood Glucose Levels and Outcomes
Whatever the clinical outcomes, higher AGLs were associated with a decreased rate of good outcomes (Table 3) . Conversely, higher AGLs were associated with an increased rate of adverse outcomes (90-day mortality and hemorrhagic complications). In multivariate analysis, AGL remained significantly associated with all outcomes, except with early neurological improvement (adjusted OR per 1 SD increase, 0.83; 95% CI, 0.66-1.04; P=0.10). In patients who received IA therapy, 
Systematic Review
The literature search identified 15 735 citations, of which 218 full articles were read and 55 were judged eligible for inclusion in the systematic review ( Figure II in the online-only Data Supplement). The main baseline characteristics, treatment strategies, and outcomes (definitions and incidences), with a brief description of direction of association between diabetes mellitus and outcomes or between AGL and outcomes are summarized in Table II in the online-only Data Supplement.
Diabetes Mellitus and Outcomes
The available unadjusted estimates of the effect of diabetes mellitus on functional outcome and sICH in individual and combined studies (including our results) are shown in the Figure 1 . Combining the available unadjusted results for functional outcome (19 studies, n=21 368), the incidence of good outcome was significantly lower in patients with history of diabetes mellitus than in those without ( Figure 1A) . A similar result was found in sensitivity analysis excluding SITS-ISTR (combined OR, 0.65; 95% CI, 0.56-0.76), or restricted to studies that analyzed favorable outcome (combined OR, 0.77; 95% CI, 0.73-0.80) or combining the available multivariate ORs (6 studies; n=19 364; Table 4 ). When combining the available unadjusted results for sICH outcome (13 studies; n=21 564), we found a significant increase in sICH risk for patients with history of diabetes mellitus ( Figure 1B) . A similar result was found when the National Institute of Neurological Disorders and Stroke (NINDS) definition was used in SITS-ISTR (combined OR, 1.38; 95% CI, 1.21-1.56) or when this study was excluded (combined OR, 1.57; 95% CI, 1.19-2.07). However, when we combined the available multivariable results (5 studies, n=18 478), the association between diabetes mellitus and sICH was no longer significant (Table 4) . 
AGLs and Outcomes
Combining the available unadjusted effect sizes (calculated as the standardized mean differences; 21 studies, n=22 042), patients with good outcome had a significantly lower AGL than patients without good outcome (Figure 2A) . A similar result was found in sensitivity analysis excluding SITS-ISTR (pooled effect size, −0.26; 95% CI, −0.18 to −0.33), or restricted to studies that analyzed favorable outcome (pooled effect size, −0.26; 95% CI, −0.17 to −0.36), or excluding the approximate effect sizes (pooled effect size, −0.28; 95% CI, −0.20 to −0.36). Regarding sICH outcome, patients with sICH had a significantly higher AGL than patients without sICH ( Figure 2B ). A similar difference was found when the NINDS definition was used in SITS-ISTR (pooled effect size, 0.30; 95% CI, 0.19-0.40) or when this study was excluded (pooled effect size, 0.28; 95% CI, 0.14-0.42), or when the approximate effect sizes were excluded (pooled effect size, 0.33; 95% CI, 0.18-0.47). When combining the available multivariable results (calculated as ORs per 18 mg/dL of glucose), AGL remained associated with poor outcome and sICH (Table 4) .
Discussion
In the present meta-analysis, history of diabetes mellitus and AGL were associated with lower rate of good outcome after thrombolysis. In addition, AGL was significantly associated with increased risk of sICH, which was not observed in patients with history of diabetes mellitus. In patients eligible for IA thrombolysis in our clinical registry, there was no documented effect of AGL on recanalization rates.
Arterial recanalization grade and speed has been reported to be one of the strongest predictors of favorable outcome after thrombolysis. 20 In 2 previous IVT studies, AGL 11 or diabetes mellitus 12 were associated with lower recanalization rates, suggesting an impaired fibrinolytic response in the setting of elevated blood glucose concentration. Evidence supports the contribution of both chronic and acute hyperglycemia to coagulation activation, 28, 29 whereas hyperinsulinemia decreases fibrinolytic activity by increasing the production of plasminogen activator inhibitor. 30, 31 In contrast with these data, we did not find any association between recanalization and AGL or diabetes mellitus in IAT-treated patients. These results are in accordance with other previous IAT studies. [14] [15] [16] [17] [18] [19] The antifibrinolytic effect of hyperglycemia may be overcome by direct IAT and mechanical endovascular techniques explaining the difference between the IVT and IAT studies. 32 The poorer clinical prognosis associated with AGL in case of IAT would therefore not be related to a recanalization rate difference, suggesting other underlying mechanisms.
Hyperglycemia and diabetes mellitus are strongly linked to increased risk of sICH after thrombolytic treatment. 33, 34 Experimental studies showed that diabetes mellitus and hyperglycemia are associated with blood-brain barrier and microvasculature impairments, as well as increased hemorrhagic infarct conversion after reperfusion. 35 Recently, blood-brain barrier disruption after IAT was associated with AGL 36 suggesting that the detelerious effect on clinical outcome of hyperglycemia may be secondary to a blood-brain barrier disruption and subsequent sICH. Hyperglycemia is also independently associated with reduced salvage of perfusiondiffusion lesion mismatch tissue, larger final infarct volume, and poor clinical outcome. 4 This effect on the penumbra might also explain why hyperglycemia is not associated with worse outcome in lacunar stroke because a penumbra is usually not present in this subtype of stroke. 37 Hyperglycemia can cause a worse clinical outcome despite recanalization with a markedly larger increase of the infarction volume. 38 Although restoration of the blood flow to the ischemic tissue is essential for penumbral salvage, reperfusion itself can also induce injury; and hyperglycemia is associated with increased reperfusion injury. 8, 39 Despite all these supporting data, and pending the results of ongoing randomized trials, such as stroke Hyperglycemia Insulin Network Effort (SHINE) trial, 40 to date, no clinical trial shows that glucose-lowering treatment improves clinical outcome in patients with AIS. 41, 42 Hyperglycemia could therefore be only a surrogate marker of larger infarct volume, explaining why interventional studies on hyperglycemia were all inconclusive.
The major limitations of our analysis were the use of observational data, including: the lack of available adjusted results or adequate data to estimate the adjusted effect sizes in a significant number of studies (which was explained by the difference in objectives between the present systematic review and previous studies); the absence of data on glucose levels time course, HbA1C values, diabetes mellitus' duration, and type of diabetes mellitus treatment; and the intrinsic biases in baseline characteristics of nonrandomized studies. In patients treated by the endovascular approach, other unavailable data may influence clinical prognosis, such as infarct volumes or collateral flow. Due to multiple comparisons (particularly done in our registry analysis), we cannot exclude the possibility of false-positive association. Finally, the presence of microbleeds or leukoaraiosis, conditions related to hemorrhagic risk, 43 were not documented in our registry or in the retrieved studies, which is a potential source of heterogeneity in our findings. In summary, AGL and history of diabetes mellitus are associated with poor clinical outcome in AIS patients treated by IV or IA thrombolysis. However, the causal relationship between AGL and worse prognosis remains undetermined and needs randomized controlled evidences, such as the ongoing SHINE trial. In fact, only data brought by a large multicenter trial may indicate the role of therapeutic intervention on glycemia in the setting of acute stroke, if any.
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